Protecting high-risk groups is a key focus of prevention and control. Recombinant protein vaccines may be the key as booster shots.
Published Time:
2022-03-25
With daily new local infections exceeding 1,000, improving the protection of high-risk groups is the current priority.
Omicron has been around for over three months now, and this currently strongest variant has triggered a new wave of the epidemic in many countries and regions around the world.
Take Hong Kong, China, as an example. In the past two years, Hong Kong's epidemic prevention strategy has been very effective against the original strain and other variants. However, problems arose when facing Omicron, which is highly contagious and has strong immune escape capabilities, especially when a large number of elderly people have not been fully vaccinated.
The number of COVID-19 deaths in Hong Kong has exceeded 100 in recent days. Comparing it with other developed countries and regions, we can find that the biggest problem in Hong Kong's vaccination is the low vaccination rate among the elderly. As of March 10, only 32% of elderly people over 80 years old in Hong Kong have received at least one dose of the vaccine, compared with 96% in Japan, where 96% of the elderly in this age group have been fully vaccinated.
Various data show that the risk of severe illness and death from COVID-19 infection is much higher for the elderly than for young and middle-aged people. Most of the recent deaths in Hong Kong are elderly people, with a median age of over 80. From December 31 last year to March 5 this year, among the total 1,556 deaths in Hong Kong, 1,073 (68.96%) were elderly people over 80 years old, and the data from other countries and regions also show this trend.
Therefore, the most important thing now is to improve the vaccination rate of the elderly and other high-risk groups as much as possible, especially using vaccines with strong protection against Omicron. Currently in mainland China, the main vaccines used are inactivated vaccines (accounting for over 90%). What kind of booster shot can be used on the basis of two doses of inactivated vaccines to improve protection has become one of the most important issues.
Some time ago, Fudan University published an important study in BMC Medicine, evaluating the long-term neutralizing antibody dynamics and predicting their protection and immunity levels based on the neutralizing antibody data of several vaccines.
The vaccines included two mRNA vaccines, two protein subunit vaccines, and one inactivated vaccine:
-Moderna (mRNA-1273)
-Pfizer (BNT162b2)
-Novavax (NVX-CoV2373)
-Lizhu (V-01)
-Sinovac (CoronaVac)
The last two are our domestically produced vaccines. Let's just look at the performance of the domestically produced vaccines.
Based on the changes in antibody levels, the estimated effectiveness of three doses of Lizhu and three doses of Sinovac against the original strain:
Infection prevention: 97% vs 65%;
Prevention of symptomatic infection: 99% vs 81%;
Prevention of severe illness: 99% vs 97%.
We can see that compared with inactivated vaccines, Lizhu shows a stronger level of protection.
However, compared with the original strain, people may be more concerned about Omicron now. First, it is the main variant at present; second, its vaccine escape ability and infectivity are stronger. Moreover, what is more important now is whether homologous boosting (a third dose of inactivated vaccine) or heterologous boosting (a third dose of another type of vaccine) is more effective after two doses of inactivated vaccines?
Some studies have shown that heterologous boosting based on inactivated vaccines may result in a higher level of protection. Here, Lizhu mentioned in the Fudan study is used as an example.
In the Lizhu study, 5-7 months after receiving two doses of inactivated vaccines, booster vaccinations were given using inactivated vaccines, Lizhu prototype vaccine (V-01), and Lizhu bivalent vaccine (a mixture of Delta and Beta), which are one homologous boosting and two heterologous boosting methods. The results showed (here we will not look at the original strain, only the live virus neutralizing antibody GMT of Omicron):
That is, in the live virus neutralization test, the neutralization levels of Lizhu prototype vaccine and bivalent vaccine were 4.9 and 11.2 times that of the inactivated vaccine, respectively. After boosting with the bivalent vaccine, the neutralization level (GMT=77) for Omicron is equivalent to the neutralization level (GMT=84) of three doses of inactivated vaccine against the original strain. The reason why the bivalent vaccine can provide stronger protection may be that the bivalent vaccine has greater differences in antigenic epitopes, inducing stronger and broader neutralizing antibody levels.
This is laboratory data. In Phase III clinical trials in Pakistan and Malaysia, using Lizhu vaccine (V-01) as a booster after two doses of inactivated vaccines resulted in an absolute protection rate of 61.35% against Omicron.
(Absolute protection rate is the effectiveness relative to the blank population (uninfected + unvaccinated population) as defined by WHO, equivalent to the effectiveness of other vaccines in Phase III clinical trials.)
As mentioned above, the protection of vaccines for the elderly may be a more important issue during the Omicron outbreak, because the virulence of Omicron is relatively weak (mainly due to the decrease in replication ability in the lungs), the rate of severe illness in young and middle-aged people is lower than that of the original strain and Delta, but the threat to the elderly is still high. In the Phase III clinical trial in Pakistan and Malaysia mentioned above, through the analysis of population subgroups, we found that Lizhu vaccine still has high protection for high-risk groups,
-Protection for high-risk groups (60 years old or with underlying diseases): 61.19%;
-People with underlying diseases: 71.83%
According to the actual efficacy data of sequential booster studies 28-84 days, using Lizhu vaccine as a booster based on two doses of inactivated vaccines can effectively combat Omicron infection.
Therefore, a large number of studies have shown that heterologous boosting with protein subunit vaccines such as Lizhu vaccine based on inactivated vaccines may result in a higher level of protection. Under the rampant Omicron, when almost standard vaccination cannot provide sufficient protection, how to adjust the vaccination strategy has become one of the most important issues. Solving this problem may require several conditions: 1. The foreign epidemic naturally subsides; 2. No stronger strains appear temporarily; 3. We have highly effective booster vaccines and large-scale vaccination. Some factors are beyond our control, but we are confident that we can develop more effective vaccines and vaccinate the general public widely.
We look forward to more good news from our domestically produced vaccines.
From: "Zhengjing Finance"